Optimizing Biologic Therapy and Eosinophil Assessment Based on GOLD 2026 Recommendations - Exacerbations and Eosinophils: Critical Assessments in COPD - CME - Guideline Central

CME

Title
Optimizing Biologic Therapy and Eosinophil Assessment Based on GOLD 2026 Recommendations - Exacerbations and Eosinophils: Critical Assessments in COPD
Link
Description
COPD remains a leading cause of morbidity and mortality, with exacerbations driving disease progression, healthcare utilization, and diminished quality of life. Even with advances in inhaled therapies, clinicians continue to face real-world challenges, from recognizing and assessing exacerbations to integrating biomarker-guided care and applying evolving Global Initiative for Obstructive Lung Disease (GOLD) treatment pathways, including biologic options, in everyday practice. In this interactive webcast expert faculty will discuss how to navigate key challenges, translate emerging evidence into clinical practice, and optimize care for your patients.
Target Audience
This educational program is designed for pulmonologists, internal medicine clinicians, and nurse practitioners and physician assistants involved in the management of patients with chronic obstructive pulmonary disease (COPD).
Learning Objectives
  • Implement strategies for earlier intervention and escalation to reduce future exacerbation risk in patients with COPD
  • Discuss challenges and solutions for the effective use of biomarker assessment in management of COPD
Estimated Duration
45 minutes
Delivery Mode
Online
Format
Online Learning
Specialties
Pulmonology, Internal Medicine - General, Primary Care
Keywords
chronic obstructive pulmonary disease (COPD), COPD exacerbation, lung disease, COPD
Disclosures and Disclaimers
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
Accredited Providers
  • Integrity CE
Commercial Support
  • Regeneron Pharmaceuticals, Inc
  • Sanofi US
Activity Expiration Date
May 15, 2027
Credit Information
Credit TypeUnits / Unit TypeBoard
AMA PRA Category 1 Credit0.75 CreditsACCME- Accreditation Council for Continuing Medical Education
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.